this was much less marked than in the Sjogren's biopsy specimens. Interferon-y staining, but not interferon-a or ,B, was also considerably enhanced in the biopsy specimens from the patients with Sjogren's syndrome. These data support the view that in Sjogren's syndrome the release of interferon-y may be involved in the induction of class II determinants. Our observations were broadly similar in both primary and secondary Sjogren's syndrome except that patients with primary Sjogren's syndrome tended to have more diffusely scattered T lymphocytes.
Sjogren's syndrome is an autoimmune disorder characterised histologically by a primarily lymphocytic infiltration of the salivary and lachrymal glands. Plasma cells are also commonly found in the cellular infiltrate which accompanies the coincident destruction of the acinar tissue and proliferation of the ducts. Most patients with Sjogren's syndrome may be divided into those with primary disease, dry eyes and mouth alone, and those with secondary disease, in whom these symptoms are set against a background of another autoimmune rheumatic disease such as systemic lupus erythematosus or rheumatoid arthritis.
In a previous study ot labial biopsy specimens from patients with secondary Sjogren's syndrome we showed that most of the infiltrating cells were group.bmj.com on June 23, 2017 -Published by http://ard.bmj.com/ Downloaded from conventional methods when multiple layers of APAAP complexes are used.
Results
The results using the nine monoclonal antibodies are shown in Tables 3, 4 , and 5. With the monoclonal antibody identifying the HLA class I determinants (2A1) considerable staining was seen in the acini, ducts, and lymphocytes of the patients with both primary and secondary Sjogren's syndrome (Fig. 1) . There were few infiltrating lymphocytes seen in the biopsy specimens from the healthy controls, but some staining of the ducts and acini was found, though this was clearly less than that found in patients with Sjogren's syndrome (Fig. 2) .
UCHT1 was used to ascertain the presence of T lymphocytes and confirmed that focal collections of these cells were frequently present in the biopsy specimens from patients with secondary Sjogren's syndrome. In contrast, patients with primary Sjogren's syndrome tended to have diffusely scattered T lymphocytes. T lymphocytes were rarely identified in the normal controls.
Although the presence of class II antigens in the ducts and acini varied in both intensity and distribution in different patients, most of the lymphocytes were stained in all patients, indicating that these cells were activated (Fig. 3) . At Very little staining was seen with anti-Tac (CD25). One of the patients with primary Sjogren's syndrome showed strong staining of one acinus. the significance of which is unclear. Weak staining on some ducts and acini was seen on another patient. but this showed weak generalised staining and was probably not significant. In the patients with secondary Sjogren's syndrome, weak staining was seen on macrophages and ducts of one patient and very weak staining on ducts and lymphocytes of another. No other staining was seen in normal controls.
Having assessed the biopsies as described, we reanalysed serial sections from four patients taken at random and the controls, to try to correlate the expression of the class I and II antigens with interferon-y. Compared with the normals, HLA class I antigens were much more strongly expressed on the acini, ducts, and infiltrating lymphocytes. There was a similar increase in HLA class II expression on the acini and lymphocytes, but the increase in duct staining was far more variable. In contrast, increased interferon-y expression was most marked in the ducts, rather less on the acini, and little increased on the lymphocytes. Discussion Evidence has recently accumulated which emphasises the potential role of class II It is noteworthy that despite the infiltrates these patients had a paucity of the usual sicca complex symptomatology, implying that lymphocytic infiltration cannot be the only cause of impaired exocrine glandular dysfunction. This suggestion is supported by our observation that one of our healthy controls had a lymphocytic infiltrate.
We were interested to examine the relation between the HLA class I and II expression with interferon and, IL2 and the IL2 receptor detection. In our studies of polymyositis we were not able to detect HLA class I antigens in normal muscle.5 It was found only in areas of myofibre damage or along the sarcolemma/basement membrane of normal looking fibres which were adjacent to the inflammatory infiltrate. Furthermore, interferon-a, IS, and y expression was closely matched to that of the HLA class I antigens.6
In labial biopsy specimens from the healthy controls there was evidence of both HLA class I and class II expression in both ducts and acini, though it was less marked than in the specimen from patients with either primary or secondary Sj6gren's syndrome. This suggests that the mechanisms of tissue damage may be different in Sjogren's syndrome than in myositis, though increased HLA expression may potentiate other mechanisms.
Analysis of the results with the monoclonal antibodies identifying the interferons showed some major differences when compared with our studies in polymyositis. Instead of the rather similar patterns that we found in myositis with each of the three interferons, our results in this study showed obvious differences between them. For example, there was very little evidence of any interferon-1 expression in any of the biopsy specimens. There was generally weak but persistent interferon-a expression in the ducts and acini in both primary and secondary Sjogren's syndrome, though this was more obvious in the former. Interferon-y staining in the ducts was very striking, especially in the patients with primary Sjogren's syndrome. This evidence lends some support to the view expressed by Fox et al that interferon-y is produced locally and induces class II determinants. ' Anatomically, however, it is difficult to be certain that the same cells showing increased HLA class I and II expression are also those which show increased expression of interferon-y. Further studies using double labelling will answer this point. 
